Increasing Enoxaparin Dosing from 30 mg to 40 mg Does Not Affect Bleeding or VTE Risk in Bariatric Surgery Patients

Abstract

Get full access to this article

View all access options for this article.

References

American Society for Metabolic and Bariatric Surgery Clinical Issues Committee . ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis. 2013;9(4):493-497.

Hamad

Choban

. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg. 2005;15(10):1368-1374.

Birkmeyer

Finks

Carlin

, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Arch Surg. 2012;147(11):994-998.

Gelikas

Eldar

Lahat

. Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. Surg Obes Relat Dis. 2017;13(10):1753-1759.